- Home
- GYRE vs ORGO Comparison
GYRE vs ORGO Comparison
Compare GYRE & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GYRE | ORGO |
|---|---|---|
| Founded | 2002 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 755.7M | 624.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GYRE | ORGO |
|---|---|---|
| Price | $7.31 | $5.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $17.00 | $8.00 |
| AVG Volume (30 Days) | 62.8K | ★ 1.6M |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | $107,265,000.00 | ★ $465,218,000.00 |
| Revenue This Year | $11.59 | $8.14 |
| Revenue Next Year | $26.31 | $6.33 |
| P/E Ratio | $189.32 | ★ N/A |
| Revenue Growth | 2.13 | ★ 2.24 |
| 52 Week Low | $6.11 | $2.61 |
| 52 Week High | $14.42 | $7.08 |
Technical Indicators
Market Signals| Indicator | GYRE | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 40.92 | 65.12 |
| Support Level | $7.36 | $4.66 |
| Resistance Level | $7.70 | $5.83 |
| Average True Range (ATR) | 0.36 | 0.23 |
| MACD | -0.06 | 0.04 |
| Stochastic Oscillator | 9.85 | 92.02 |
Price Performance
Historical ComparisonAbout GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.